|
Managing hypertension
|
23
|
100.0%
|
75
|
80.6%
|
29
|
93.5%
|
0.02
|
|
Managing hypertension in patients with CKD
|
16
|
69.6%
|
47
|
50.0%
|
24
|
77.4%
|
0.01
|
|
Managing hypertension in patients with CKD with DM
|
15
|
65.2%
|
52
|
55.3%
|
23
|
74.2%
|
0.16
|
|
Achieving lowered blood pressure in patients with CKD
|
17
|
73.9%
|
37
|
39.4%
|
19
|
61.3%
|
0.00
|
|
Interpreting eGFR to stage CKD
|
20
|
87.0%
|
58
|
61.7%
|
25
|
80.6%
|
0.02
|
|
Monitoring eGFR in patients with CKD
|
20
|
87.0%
|
58
|
61.7%
|
24
|
77.4%
|
0.03
|
|
Monitoring eGFR in CKD patient with DM
|
16
|
69.6%
|
48
|
51.1%
|
25
|
80.6%
|
0.01
|
|
Using urine protein results to manage DM
|
15
|
65.2%
|
37
|
39.4%
|
18
|
58.1%
|
0.03
|
|
Using urine protein results to manage CKD
|
12
|
52.2%
|
35
|
37.2%
|
15
|
48.4%
|
0.31
|
|
Using ACE inhibitors and/or ARB
|
22
|
95.7%
|
71
|
75.5%
|
26
|
83.9%
|
0.08
|
|
Using ACE inhibitors and/or ARB in patients with CKD
|
19
|
82.6%
|
55
|
58.5%
|
24
|
77.4%
|
0.03
|
|
Using other anti-hypertensives in patients with CKD
|
18
|
78.3%
|
54
|
57.4%
|
23
|
74.2%
|
0.08
|
|
Adding a loop diuretic drug (e.g. furosemide) to patients with CKD already on maximum dose of an ACE I and/or ARB
|
7
|
30.4%
|
26
|
27.7%
|
16
|
51.6%
|
0.05
|
|
Using referral guidelines to refer appropriate patients with DM to secondary care
|
12
|
52.2%
|
51
|
54.3%
|
26
|
83.9%
|
0.01
|
|
Using referral guidelines to refer appropriate patients with CKD to secondary care
|
13
|
56.5%
|
43
|
45.7%
|
25
|
80.6%
|
0.00
|
|
Overall management of patients with DM
|
15
|
65.2%
|
54
|
57.4%
|
26
|
83.9%
|
0.03
|
|
Overall management of patients with CKD
|
9
|
39.1%
|
44
|
46.8%
|
22
|
71.0%
|
0.03
|
